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Summary
Background: Very little information is available on the drug susceptibility profile among patients who are treated with
standardized short-course chemotherapy regimens under programme conditions.
Methods: Sputum samples were collected from new sputum smear-positive patients declared ‘failure’ after treatment with
Category I regimen under tuberculosis control programme using DOTS strategy from a rural area of Tamil Nadu.
Results: Of 1463 patients started on Category I regimen between May1999 and December 2002, 74 cases were declared
as ‘failures’ (smear positive at 5/6 months of treatment). We collected sputum samples from 60 (81%) of 74 ‘failures’ and
27% (16 of 60) of them were culture-negative for M tuberculosis and 17% (10 of 60) had organisms resistant to Isoniazid
and Rifampicin (MDR TB).
Conclusion: Based on the drug susceptibility profile at the time of ‘failure’, treating Category I ‘failures’ with Category
II regimen with close monitoring appears to be justified.
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INTRODUCTION
According to WHO’s DOTS strategy, newly
diagnosed sputum smear positive (NSS) patients
with pulmonary tuberculosis who remain sputum
smear positive after 5-months of treatment with
Category I regimen consisting of  2H3R3Z3E3/4
H3R3are declared as ‘failures’.  They are treated with
Category II regimen1 consisting of  2S3H3R3Z3E3/
1H3R3 Z3E3/ 5H3R3E3.
An earlier report from the same area from
our Centre had reported the significant risk factors
for failure among Cat I patients to be non-conversion
of sputum smear at the end of intensive phase, initial
resistance to H and/or R, and smoking2.
Recently, concerns have been expressed that
treatment with Category II regimen may not be
effective for such re-treatment cases.  It has been
suggested that they may be treated with a stronger
regimen since such cases are likely to harbour drug-
resistant organisms3-5.  We examined the drug
susceptibility profile of category I failure cases in a
DOTS programme in rural Tamil Nadu to examine if
these concerns had any basis.
MATERIAL  AND  METHODS
The study was conducted in a sub-district
population of 580,000 in Tamil Nadu.  Under the
DOTS programme, tuberculosis (TB) cases were
detected at 17 primary- and secondary-level
governmental health facilities by screening ‘chest
symptomatics’ using the diagnostic algorithm of
Revised National Tuberculosis Control Programme
(RNTCP) 6. NSS cases were treated with Category
I regimen, consisting of Rifampicin (R), Isoniazid
(H), Ethambutol (E) and Pyrazinamide (Z) given
three-times-a week during the intensive phase of 2-
months and R and H three-times-a-week during the
continuation phase of 4-months. Treatment
outcomes were defined according to international
guidelines 1.
The study population consisted of all NSS
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pulmonary TB patients who registered for DOTS
treatment during May 1999 to December 2002 and
were treated with the Category I regimen6. Additional
sputum samples were collected from study subjects
in sterile containers with Cetyl Pyridinium Chloride
by the laboratory technicians of the respective
centres at two time points, namely, on starting
treatment and at 5/6 months after starting treatment,
if sputum smear was positive.  Sputum samples were
cultured for M.  tuberculosis on Lowenstein Jensen
(L-J) medium7 . The positive cultures were subjected
to drug susceptibility for Isoniazid (H) and
Rifampicin (R) by minimal inhibitory concentration
(MIC) method8.  Resistance was defined as an MIC
of 5mg or more for Isoniazid and 128mg for
Rifampicin8.
The data were computerized and analysed
using Epi- Info version 6.04d (Centres for Disease
Control, Atlanta, GA). Independent risk factors and
adjusted odds ratios (AOR) were obtained by stepwise
logistic regression analysis using SPSS/PC+, version
13.0. The criterion for inclusion of variables in logistic
regression was set at P<0.1 and 95% confidence
intervals were calculated.
RESULTS
In all, 1463 study patients were registered
between May 1999 and December 2002. Sputum
was collected from 1395 (95%) and drug susceptibility
profile was available for 1226 patients, 158 were
negative on culture and 11 were contaminated. Of
the 1226, 1094 (89%) had organisms susceptible to
H and R, 111 (9%) resistant to H, 16 (1.3%) to H
and R (Multi-Drug Resistant) and 5 (0.4%) to R
alone.
Treatment outcome of the 1463 patients was
as follows: 1117 (76%) had a successful treatment
outcome, 212 (14.5%) had defaulted, 58 (4%) died,
74(5%) were declared to have failed while two were
transferred out. Risk factors identified for failure
were non-conversion of sputum smear at the end of
intensive phase (AOR 2.6; 95% CI=1.5-4.5), initial
resistance to H and/or R (AOR 11.2; 95% CI=6.4-
19.6), and smoking  (AOR 1.9; 95% CI=1.1-3.3)
(data not tabulated).
Of the 74 failure cases, sputum samples
were collected from 60 (81%) patients at the time
of failure. Pre-treatment characteristics like age, sex,
and initial smear grading, drug regularity and sputum
conversion were similar among patients from whom
sputum was not collected to those from whom
sputum was collected (data not tabulated).  Of the
60 cases from whom sputum was collected, 16
(27%) were negative on culture, 10 (17%, 95% CI:
Culture status and sensitivity pattern at failure 
              
     Resistant to 
Sensitivity 
pattern (pre-
treatment) 
Total 
patients 
 
Failure 
No.   % 
 
Sputum 
collected 
Sens. H H and R    S+C- 
Sensitive  1094 34      3 26 14   1 - 11 
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H 
R 
HR 
 
111 
   5 
16 
 
23     21 
  1     20 
  7     44 
 
20 
 0 
 7 
 
  - 
  - 
  - 
 
16 
  - 
  - 
 
3 
- 
6 
 
  1 
  - 
  1 
S+C-**   158   5       3  4   2   1 -   1 
Not available   79*   4       5  3   -         - 1   2 
Total 1463 74       5 60 (81%) 16 (27%) 
 
18 (30%) 
 
10 (17%) 
 
16 (27%) 
 
* 11 with culture contamination and 68 with no sputum collection
** Smear positive Culture Negative
Table: Drug susceptibility profile pre-treatment and at the time of failure among patients treated with
Category I regimen
SANTHA  T  ET  AL204
Indian Journal of Tuberculosis
7-26) had MDR TB {of these, 6 had MDR TB at the
time of starting treatment (Table 1)}. Further, 18
(30%) had H resistant organisms (16 had initial H
resistance).
DISCUSSION
Under programme conditions, patients are
declared ‘failed’ on Cat I regimen if smears become
positive at 5-month or more after starting treatment.
In our series, of the 74 patients declared to have
‘failed’, MDR TB (organisms resistant to H and R)
was seen among 17% justifying the use of Cat II
regimen for failures of Cat I treatment for the
remaining 83% of patients. Thus, all failures do not
have MDR TB.
A study from Vietnam3 had reported 80%
of Category I failure cases to have MDR TB. The
regimen, 2SHRZ/6HE used for treatment in Vietnam
differed from the 2REHZ3/HR3 used in this
programme. In the study from Vietnam, emergence
of drug resistance was considered only for patients
who had RFLP matching cultures at pre-treatment
and at the time of failure. A programme-based study
from Malawi 9 had reported that none of the failures
to first line treatment with 6HE in the continuation
phase following an intensive phase of either 2SHRZ
or 2HRZE3 had MDR TB.
In controlled clinical trial using standardized
short-course regimens for treating NSS patients10,
81% of 320 patients with H resistance, had favourable
treatment outcome and 13% had bacteriological
relapse, respectively, during a 24-month period of
follow up. Thus, 18 patients with resistance to H at
the time of failure also are likely to respond to
treatment with Cat II regimen. Another 27% were
negative by culture and there is no cause for concern
in treating these patients with Category II regimen.
Our finding that non-conversion at the end
of intensive phase to be a significant risk factor for
failure suggests that patients who remain smear-
positive at the end of intensive phase need to be
interrogated for prior anti-tuberculosis treatment. If
such a history is forthcoming, treatment may be
changed to Cat II regimen.
A change in the present policy to use
‘stronger regimens’ for these patients will have other
implications. Although the proportion of failures is
small, in a high burden country such as India, the
absolute number of failures is high. For example, in
2002, of 358,496 NSS patients treated, there were
around 9500 failures (Central TB Division, India:
Personal communication). Providing culture and drug
susceptibility testing for such a large number of
patients across the country is logistically and
economically non-feasible in low-income countries.
Hence, in high burden countries without access to
culture and drug susceptibility testing, all these
patients will have to be treated with second line drugs.
In conclusion, our finding that nearly
80% of the ‘failures’ (as declared in the
programme, based on smear results), have
organisms susceptible to R, justifies the use of
the currently recommended category II regimen
for failures of category I treatment. Close
monitoring of these patients will be required to
identify failures early and if necessary, change
of treatment can be considered for those patients
who do not show any response to treatment with
Cat II regimen at 3-months.
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